Suppr超能文献

心脏移植受者术后即刻口服环孢素(新山地明)的药代动力学

Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.

作者信息

Banner Nicholas R, David Olivier J, Leaver Neil, Davis Julie, Breen Jane, Johnston Atholl, Yacoub Magdi H

机构信息

Heart Failure and Transplant Service, Royal Brompton and Harefield NHS Trust, Harefield Hospital, Hill End Road, Harefield, Middlesex UB9 6JH, UK.

出版信息

Transpl Int. 2002 Dec;15(12):649-54. doi: 10.1007/s00147-002-0491-0. Epub 2002 Nov 22.

Abstract

Neoral cyclosporine has better absorption characteristics than the original Sandimmun formulation. This has allowed Neoral to be administered orally in circumstances where Sandimmun had been ineffective, including the postoperative phase of liver transplantation. Sampling strategies, such as the measurement of drug concentration 2 h after oral administration, have been used in a variety of settings to estimate systemic exposure to Neoral (measured as the area under the blood concentration curve (AUC) of the drug) in blood. We conducted a pilot study to determine whether Neoral could be administered orally immediately after heart transplantation and to determine which pharmacokinetic parameters reflect systemic drug exposure in this setting. Eight male patients (mean age 50 years) undergoing a first heart transplant were studied. Neoral was administered orally before surgery and at 12-h intervals via a nasogastric tube after surgery. Twelve-hour pharmacokinetic profiles were obtained on postoperative days 1, 3 and 5. Cyclosporine concentrations were measured with the Dade Behring Emit assay, which is specific for the parent drug. Drug concentrations were dose-normalised and drug exposure was measured by the AUC. Drug exposure following administration (AUC(0-12)) was low on day 1 but increased by 99% between postoperative day 1 and day 5 ( P<0.05), indicating more complete absorption of cyclosporine; exposure in the first 4 h post-dose (AUC(0-4)) increased by 126% ( P<0.01), reflecting more rapid cyclosporine absorption, and the maximum blood concentration observed increased by 137% ( P<0.05) during the same period. The correlation between the cyclosporine trough concentration and AUC(0-12) was low on all days. Due to the changing pattern of cyclosporine absorption, concentration measurements at a single time point could not accurately predict 12-h exposure to the drug on all study days. However, the drug concentration at 2 h post-dose had a high correlation with drug exposure during the first 4 h (correlation of C(2) to AUC(0-4): r(2)>0.93 on all days). Absorption of Neoral was low immediately after heart transplantation but improved substantially during the first 5 days after surgery. No single timed measurement of drug concentration reflected cyclosporine exposure; however, the 2-h concentration did provide an accurate measure of the early phase of drug absorption (AUC(0-4)). Oral administration of Neoral may result in inadequate immunosuppression immediately after heart transplantation unless it is supplemented either by intravenous cyclosporine or by the use of an induction agent.

摘要

新山地明(Neoral)环孢素的吸收特性优于原有的山地明(Sandimmun)制剂。这使得新山地明能够在山地明无效的情况下口服给药,包括肝移植术后阶段。采样策略,如口服给药后2小时测量药物浓度,已在各种情况下用于估计血液中系统暴露于新山地明的情况(以药物血药浓度曲线下面积(AUC)衡量)。我们进行了一项初步研究,以确定心脏移植后是否可立即口服新山地明,并确定在此情况下哪些药代动力学参数反映系统药物暴露。研究了8名接受首次心脏移植的男性患者(平均年龄50岁)。术前口服新山地明,术后通过鼻胃管每12小时给药一次。在术后第1、3和5天获得12小时药代动力学曲线。用达德拜林(Dade Behring)Emit分析法测量环孢素浓度,该方法对母体药物具有特异性。将药物浓度进行剂量标准化,并通过AUC测量药物暴露。给药后的药物暴露(AUC(0 - 12))在第1天较低,但在术后第1天至第5天之间增加了99%(P<0.05),表明环孢素吸收更完全;给药后前4小时的暴露(AUC(0 - 4))增加了126%(P<0.01),反映环孢素吸收更快,同期观察到的最大血药浓度增加了137%(P<0.05)。在所有日子里,环孢素谷浓度与AUC(0 - 12)之间的相关性都很低。由于环孢素吸收模式的变化,在所有研究日,单一时间点的浓度测量无法准确预测药物12小时的暴露情况。然而,给药后2小时的药物浓度与前4小时的药物暴露高度相关(C(2)与AUC(0 - 4)的相关性:所有日子里r(2)>0.93)。心脏移植后立即口服新山地明的吸收较低,但术后前5天有显著改善。没有单一的定时药物浓度测量反映环孢素暴露情况;然而,2小时浓度确实提供了药物吸收早期阶段(AUC(0 - 4))的准确测量。心脏移植后立即口服新山地明可能导致免疫抑制不足,除非通过静脉注射环孢素或使用诱导剂进行补充。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验